Necrotizing Soft Tissue Infection in an Immunocompromised Patient

Overview

Journal Case Rep Crit Care

Publisher Wiley

Specialty Critical Care

Date 2018 May 29

PMID 29805813

Citations 5

Authors

Oleg Stens

Gabriel Wardi

Matthew Kinney

Stephanie Shin

Demosthenes Papamatheakis

Affiliations

Soon will be listed here.

Abstract

Introduction: To report on the first recorded case of necrotizing soft tissue infection (NSTI) in an immunocompromised individual caused by in the Western Hemisphere and highlight the challenges that medical providers face in promptly diagnosing and treating NSTI in this highly vulnerable patient population.

Case Presentation: We report a case of NSTI caused by in a neutropenic patient admitted for treatment of acute lymphoblastic leukemia. The patient presented with laboratory and clinical findings atypical for a NSTI that may have confounded its diagnosis and delayed surgical intervention. Despite aggressive medical care and surgical debridement, the patient unfortunately passed away due to overwhelming septic shock.

Conclusions: Providers should consider atypical organisms as causative in NSTI in immunocompromised patients and recognize that these patients may present without classic clinical and laboratory findings.

Citing Articles

Case series: Stenotrophomonas maltophilia in pediatric oncology patients.

Sarkar S, Stitzlein L, Rav E, Garcia M, Razvi S, Chang M Cancer Rep (Hoboken). 2024; 7(3):e1982.

PMID: 38419283 PMC: 10913069. DOI: 10.1002/cnr2.1982.

Advances in the Microbiology of Stenotrophomonas maltophilia.

Brooke J Clin Microbiol Rev. 2021; 34(3):e0003019.

PMID: 34043457 PMC: 8262804. DOI: 10.1128/CMR.00030-19.

Stenotrophomonas maltophilia: An Emerging Pathogen of the Respiratory Tract.

Kanderi T, Shrimanker I, Mansoora Q, Shah K, Yumen A, Komanduri S Am J Case Rep. 2020; 21:e921466.

PMID: 32448864 PMC: 7274500. DOI: 10.12659/AJCR.921466.

The skin and soft tissue infections in hematological patients.

Ungaro R, Mikulska M Curr Opin Infect Dis. 2020; 33(2):101-109.

PMID: 32022740 PMC: 9930892. DOI: 10.1097/QCO.0000000000000632.

Comparative Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against in the Murine Thigh Model.

Chen I, Kidd J, Abdelraouf K, Nicolau D Antimicrob Agents Chemother. 2019; 63(12).

PMID: 31591126 PMC: 6879223. DOI: 10.1128/AAC.01558-19.

References

Sakhnini E, Weissmann A, Oren I . Fulminant Stenotrophomonas maltophilia soft tissue infection in immunocompromised patients: an outbreak transmitted via tap water. Am J Med Sci. 2002; 323(5):269-72. DOI: 10.1097/00000441-200205000-00008. View

Ustin J, Malangoni M . Necrotizing soft-tissue infections. Crit Care Med. 2011; 39(9):2156-62. DOI: 10.1097/CCM.0b013e31821cb246. View

SANYAL S, Mokaddas E . The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother. 1999; 11(1):28-33. DOI: 10.1179/joc.1999.11.1.28. View

Vartivarian S, Papadakis K, Palacios J, Manning Jr J, Anaissie E . Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia. A new spectrum. Ann Intern Med. 1994; 121(12):969-73. DOI: 10.7326/0003-4819-121-12-199412150-00011. View

Safdar A, Rolston K . Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis. 2008; 45(12):1602-9. DOI: 10.1086/522998. View

Keung E, Liu X, Nuzhad A, Adams C, Ashley S, Askari R . Immunocompromised status in patients with necrotizing soft-tissue infection. JAMA Surg. 2013; 148(5):419-26. DOI: 10.1001/jamasurg.2013.173. View

Elting L, Khardori N, Bodey G, Fainstein V . Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol. 1990; 11(3):134-8. DOI: 10.1086/646136. View

Burner E, Henderson S, Burke G, Nakashioya J, Hoffman J . Inadequate Sensitivity of Laboratory Risk Indicator to Rule Out Necrotizing Fasciitis in the Emergency Department. West J Emerg Med. 2016; 17(3):333-6. PMC: 4899066. DOI: 10.5811/westjem.2016.2.29069. View

Brook I, Frazier E . Clinical and microbiological features of necrotizing fasciitis. J Clin Microbiol. 1995; 33(9):2382-7. PMC: 228417. DOI: 10.1128/jcm.33.9.2382-2387.1995. View

10.

Wong C, Khin L, Heng K, Tan K, Low C . The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004; 32(7):1535-41. DOI: 10.1097/01.ccm.0000129486.35458.7d. View

11.

Ansari S, Hanna H, Hachem R, Jiang Y, Rolston K, Raad I . Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer. 2007; 109(12):2615-22. DOI: 10.1002/cncr.22705. View

12.

Teo W, Chan M, Lam C, Chong C . Skin manifestation of Stenotrophomonas maltophilia infection--a case report and review article. Ann Acad Med Singap. 2007; 35(12):897-900. View

13.

Hiransuthikul N, Tantisiriwat W, Lertutsahakul K, Vibhagool A, Boonma P . Skin and soft-tissue infections among tsunami survivors in southern Thailand. Clin Infect Dis. 2005; 41(10):e93-6. DOI: 10.1086/497372. View

14.

Ellis Simonsen S, van Orman E, Hatch B, Jones S, Gren L, Hegmann K . Cellulitis incidence in a defined population. Epidemiol Infect. 2006; 134(2):293-9. PMC: 2870381. DOI: 10.1017/S095026880500484X. View

15.

Paez J, Costa S . Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect. 2008; 70(2):101-8. DOI: 10.1016/j.jhin.2008.05.020. View

16.

Nicodemo A, Paez J . Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis. 2007; 26(4):229-37. DOI: 10.1007/s10096-007-0279-3. View

17.

Neeki M, Dong F, Au C, Toy J, Khoshab N, Lee C . Evaluating the Laboratory Risk Indicator to Differentiate Cellulitis from Necrotizing Fasciitis in the Emergency Department. West J Emerg Med. 2017; 18(4):684-689. PMC: 5468074. DOI: 10.5811/westjem.2017.3.33607. View

18.

Aisenberg G, Rolston K, Dickey B, Kontoyiannis D, Raad I, Safdar A . Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004. Eur J Clin Microbiol Infect Dis. 2007; 26(1):13-20. DOI: 10.1007/s10096-006-0243-7. View

19.

Denton M, Kerr K . Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998; 11(1):57-80. PMC: 121376. DOI: 10.1128/CMR.11.1.57. View

20.

Moser C, Jonsson V, Thomsen K, Albrectsen J, Hansen M, Prag J . Subcutaneous lesions and bacteraemia due to Stenotrophomonas maltophilia in three leukaemic patients with neutropenia. Br J Dermatol. 1997; 136(6):949-52. View